"Loading Stock Price & Valuation Data ..."
Unlock News Summary by Subscribing to iPick.ai Premium!
Ask anything related to ABCL. [ FAQ on what and how to ask] For non-ABCL questions, click the logo in the upper-right corner to return to the main page and ask there.
CEO:Dr. Carl L.G. Hansen Ph.D.
Headquarter: 150 W 4th Avenue, Vancouver, BC, Canada, V5Y 1G6
Industry: Biotechnology, Investment Track: AI drug discovery, Employees: 562
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
My Watchlist
